Never like to hear this, though the filing says he's leaving to form his own company. I'm less concerned about this I think than if he were just leaving to join another existing company. Could it be the CSO took some heat for the design of the lead tivantinib trial that bombed and decided to bolt to do his own thing?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.